BioNexus Gene Lab (BGLC) Change in Acquisitions & Divestments (2021 - 2024)

BioNexus Gene Lab has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $574036.0 in Q4 2024.

• Quarterly Change in Acquisitions & Divestments rose 81178.53% year-over-year to $574036.0 in Q4 2024, while the trailing twelve-month figure through Mar 2025 was $857433.0 (up 261.04% YoY) and the FY2024 annual result came in at $1.1 million, up 3987.73% from the prior year.
• Change in Acquisitions & Divestments climbed to $574036.0 in Q4 2024 per BGLC's latest filing, from $197063.0 in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $574036.0 in Q4 2024 and troughed at -$708.0 in Q4 2023.
• A 3-year average of $136856.1 and a median of $56594.0 in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 81178.53% in 2024, down 633.83% in 2024.
• Over 3 years, Change in Acquisitions & Divestments stood at -$22.0 in 2021, then sank by 3118.18% to -$708.0 in 2023, then surged by 81178.53% to $574036.0 in 2024.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $574036.0, $197063.0, and $86334.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.